Core D: Research Support Core

项目摘要 研究支持核心(RSC)将提供广泛的高质量定量分析技术 跨越代谢组学、表观基因组学、转录组学和蛋白质组学的平台。英国皇家莎士比亚剧团的领导人是迪恩博士 BCM高级技术核心执行董事P·爱德华兹说。RSC的联合负责人是Nagireddy博士 普特鲁里也是代谢组学核心中心的主任，是公认的质谱学领导者- 基于代谢组学的图谱。皇家莎士比亚剧团有以下具体目标。目标1将有效地支持 拥有尖端定量多组学技术的超级基金项目。已确立的核心技术 可用的包括基于质谱学的靶向和无偏向代谢组学、无偏向蛋白质组图谱 通过质谱学，以抗体为基础的反相蛋白质阵列(RPPA)和 基因组学平台，如全基因组测序、RNA-seq转录组学、小RNA测序 和表观遗传学的芯片序列。RSC的支持将包括来自教职员工级别的核心主任的智力投入 咨询和实验设计，主持先进仪器，执行最先进的分析 研究人员对岩心和“组学”数据集进行处理和分析的程序。RSC技术 平台将主要用于项目2、3和4，以确定多环化合物的生物标志物和分子特征 与早产(PTB)相关的芳香烃(PAH)暴露及其分子定义 多环芳烃及其衍生物对慢性肺损伤的增强作用机制 疾病/支气管肺发育不良(BPD)与实验模型和人类的神经行为缺陷 学习。代谢组学核心还将有助于测量和量化多环芳烃及其 用GC-MS分析代谢物，作为项目中开发更灵敏和不那么复杂的分析的标准 1和2.AIM 2将继续与项目负责人和调查人员合作，以开发、验证和部署 赠款过程中的新方法，目前不是标准的核心程序。这将在最初 包括新多环芳烃衍生物和代谢物的MS鉴定，以及无偏代谢组学分析， RPPA全基因组DNA对组蛋白修饰和染色质修饰酶的表观遗传学分析 亚硫酸氢盐测序甲基化和MS氧化还原蛋白质组学方法。AIM 3将培训调查人员 设计、执行和解释英国皇家莎士比亚剧团最先进的分析技术的结果。 这将通过提供教程、研讨会和一些关于原则的实践机会来实现 超级基金拨款的调查人员及其博士后和研究生实习生。终极目标 为超级基金提供尖端的技术和最高质量的科学解决方案 研究人员用于在分子机制和遗传水平上了解多环芳烃暴露的目的。

Project Summary The Research Support Core (RSC) will provide a wide range of high quality quantitative analytical technology platforms spanning metabolomics, epigenomics, transcriptomics, and proteomics. The RSC leader is Dr. Dean P. Edwards, Executive Director of the Advanced Technology Cores at BCM. The RSC co-leader is Dr. Nagireddy Putluri, who also serves as director of the Metabolomics Core and is a recognized leader in mass spectrometry- based metabolomics profiling. The RSC has the following specific aims. AIM 1 Will effectively support the Superfund projects with cutting edge quantitative multi-omics technologies. Established Core technologies available includes mass spectrometry-based targeted and unbiased metabolomics, unbiased proteomic profiling by mass spectrometry, targeted proteomics by antibody-based reverse phase protein array (RPPA) and genomics platforms such as whole genome sequencing, transcriptomics by RNA-seq, smallRNA sequencing and epigenetics by ChIP-Seq. RSC support will include intellectual input from faculty level Core Directors for consultation and experimental design, hosting of advanced instrumentation, executing state-of-the-art analytical procedures by research staff of Cores and processing and analysis of “omics” data sets. RSC technology platforms will be used primarily in Projects 2, 3 and 4 to identify biomarkers and molecular signatures of polycyclic aromatic hydrocarbon (PAH) exposures associated with preterm birth (PTB) and to define the molecular mechanisms underlying the potentiating effects of PAH and its derivatives on chronic lung disease/bronchopulmonary dysplasia (BPD) and neurobehavioral deficits in experimental models and in human studies. The metabolomics core will additionally be instrumental for measuring and quantification of PAH and its metabolites by GC-MS as a standard for development of more sensitive and less sophisticated assays in Projects 1 and 2. AIM 2 Will continuously work with Project leaders and investigators to develop, validate, and deploy novel methods during the course of the grant that are not currently standard Core procedures. This will initially include MS identification of novel PAH derivatives and metabolites, and unbiased metabolomics profiling, epigenetic profiling of histone modifications and chromatin modifying enzymes by RPPA, genome-wide DNA methylation by bisulfite sequencing and Redox proteomics by MS methods. AIM 3 Will train investigators in designing, executing, and interpreting results of the state-of-the-art analytical techniques conducted by the RSC. This will be accomplished by providing tutorials, workshops and some hands-on opportunities for principle investigators of the Superfund grant and their post-doctoral and graduate student trainees. The ultimate goal of the RSC is to provide cutting-edge technical and the best quality scientific solutions available for the Superfund investigators for use in their Aims of understanding PAH exposures at molecular mechanistic and genetic levels.